104 related articles for article (PubMed ID: 3019978)
1. In vitro evaluation of SF-2103A, a novel carbapenem antibiotic, as a beta-lactamase inhibitor.
Niwa T; Yoshida T; Tamura A; Kazuno Y; Inouye S; Ito T; Kojima M
J Antibiot (Tokyo); 1986 Jul; 39(7):943-55. PubMed ID: 3019978
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins.
Yoshida T; Kazuno Y; Shomura T; Murata S; Inouye S; Ito T
J Antibiot (Tokyo); 1986 Jul; 39(7):956-65. PubMed ID: 3531130
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactamase inhibitory activities and synergistic effects of 5,6-cis-carbapenem antibiotics.
Okonogi K; Harada S; Shinagawa S; Imada A; Kuno M
J Antibiot (Tokyo); 1982 Aug; 35(8):963-71. PubMed ID: 6982889
[TBL] [Abstract][Full Text] [Related]
4. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
6. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
7. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
Aldridge KE; Sanders CV; Marier RL
J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.
Fu KP; Neu HC
J Antimicrob Chemother; 1981 Mar; 7(3):287-92. PubMed ID: 6268598
[No Abstract] [Full Text] [Related]
9. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
Neu HC; Fu KP
Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
[TBL] [Abstract][Full Text] [Related]
10. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzae.
Yu PK; Washington JA
Antimicrob Agents Chemother; 1981 Jul; 20(1):63-5. PubMed ID: 6269484
[TBL] [Abstract][Full Text] [Related]
13. PS-5, a new beta-lactam antibiotic. III. Synergistic effects and inhibitory activity against a beta-lactamase.
Okamura K; Sakamoto M; Fukagawa Y; Ishikura T; Lein J
J Antibiot (Tokyo); 1979 Apr; 32(4):280-6. PubMed ID: 381269
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.
Gutmann L; Kitzis MD; Yamabe S; Acar JF
Antimicrob Agents Chemother; 1986 May; 29(5):955-7. PubMed ID: 3015011
[TBL] [Abstract][Full Text] [Related]
15. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.
Crosby MA; Gump DW
Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
Neu HC
Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
[TBL] [Abstract][Full Text] [Related]
17. Sulbactam: biochemical factors involved in its synergy with ampicillin.
Labia R; Morand A; Lelievre V; Mattioni D; Kazmierczak A
Rev Infect Dis; 1986; 8 Suppl 5():S496-502. PubMed ID: 3025996
[TBL] [Abstract][Full Text] [Related]
18. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
Jarlier V
Presse Med; 1998 Sep; 27 Suppl 4():17-8. PubMed ID: 9798480
[No Abstract] [Full Text] [Related]
19. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
Chin NX; McElrath MJ; Neu HC
Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
Paukner S; Hesse L; Prezelj A; Solmajer T; Urleb U
Antimicrob Agents Chemother; 2009 Feb; 53(2):505-11. PubMed ID: 19075067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
